Holen Sie sich die Stockscreener-App
6.77
3.15%
-0.22
Vorhandelsmarkt:
6.56
-0.21
-3.10%
Schlusskurs vom Vortag:
$6.99
Offen:
$7.06
24-Stunden-Volumen:
485.91K
Relative Volume:
0.48
Marktkapitalisierung:
$409.54M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-0.8069
EPS:
-8.39
Netto-Cashflow:
$-424.74M
1W Leistung:
+3.52%
1M Leistung:
+3.20%
6M Leistung:
+14.94%
1J Leistung:
-36.13%
1-Tages-Spanne:
$6.705
$7.21
1-Wochen-Bereich:
$6.50
$7.21
52-Wochen-Spanne:
$4.62
$13.47
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
6.77 | 409.54M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-21 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Eingeleitet | Citigroup | Sell |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-04-17 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-08 | Herabstufung | Needham | Buy → Hold |
| 2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-03-31 | Eingeleitet | Berenberg | Hold |
| 2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-12-05 | Bestätigt | Guggenheim | Buy |
| 2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-23 | Eingeleitet | Wedbush | Outperform |
| 2019-04-25 | Eingeleitet | Jefferies | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - ACCESS Newswire
How To Trade (SAGE) - news.stocktradersdaily.com
Shareholders Filed a Lawsuit Against Sage Therapeutics for Failed Drug Launch - TradingView
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the FirmSAGE - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Shareholders - ACCESS Newswire
Bank of America Corp DE Sells 355,277 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
ProShare Advisors LLC Boosts Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Ameriprise Financial Inc. Trims Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Trims Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Deutsche Bank AG Buys 20,504 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Wall Street Zen Upgrades Sage Therapeutics (NASDAQ:SAGE) to “Hold” - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zurzuvae®: The Value Spills Over - Leerink Partners
Man Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Increases Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Northern Trust Corp Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - Louisiana First News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - ACCESS Newswire
What's The Risk Of Letting Researchers Use LLMs? - Clinical Leader
Sage Therapeutics (NASDAQ:SAGE) Lowered to Sell Rating by StockNews.com - Defense World
Sage Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
How the (SAGE) price action is used to our Advantage - news.stocktradersdaily.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Jane Street Group LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire
Dimensional Fund Advisors LP Reduces Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics Brass Sued Over Drug Candidate Claims - Law360
Voya Investment Management LLC Raises Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifshitz Law PLLC Announces Investigations of Extreme Networks, Inc. (NASDAQ:EXTR), Methode Electronics, Inc. (NYSE:MEI), Sage Therapeutics, Inc. (NASDAQ:SAGE), and New Fortress Energy, Inc. (NASDAQ:NFE) - Louisiana First News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Wells Fargo & Company MN Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Lost Money on Sage Therapeutics, Inc.(SAGE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Barclays PLC Decreases Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Where are the Opportunities in (SAGE) - news.stocktradersdaily.com
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial - The Globe and Mail
Sage Therapeutics (NASDAQ:SAGE) Upgraded at StockNews.com - Defense World
Invesco Ltd. Purchases 4,629 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Q2 Earnings Forecast for Sage Therapeutics Issued By Wedbush - Defense World
HC Wainwright Issues Positive Estimate for SAGE Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
What is HC Wainwright’s Forecast for SAGE Q1 Earnings? - Defense World
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.92%
7.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):